The changing landscape in metastatic castration-resistant prostate cancer

Raya Leibowitz-Amit, Anthony M. Joshua*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of review: The treatment landscape in metastatic castration-resistant prostate cancer (mCRPC) has significantly changed in the recent years. We provide an updated summary of the new therapeutic agents in this disease and discuss open questions and future challenges. Recent findings: mCRPC is now known to frequently retain sensitivity to hormonal manipulation even after the development of castration resistance, and both the androgen synthesis inhibitor abiraterone and the androgen-receptor antagonist enzalutamide have recently shown to prolong survival in mCRPC patients after chemotherapy. Cabazitaxel, a new-generation antitubulin chemotherapeutic, and the radionuclide radium-223 chloride have also been shown to prolong survival. The biological agent cabozantinib, an orally bioavailable tyrosine kinase inhibitor with activity against Met and vascular endothelial growth factor receptor 2, demonstrated promising results in a phase II trial and is currently being assessed in two large randomized phase 3 controlled trials. Summary: This recent progress is unprecedented and has already translated to a significant increase in the available armamentarium of drugs for mCRPC. Nonetheless, there are still significant unresolved questions as to the proper sequencing of these novel drugs along the disease continuum. Moreover, the problem of drug resistance, either primary of acquired, continues to be a major therapeutic obstacle.

Original languageEnglish
Pages (from-to)243-248
Number of pages6
JournalCurrent Opinion in Supportive and Palliative Care
Volume7
Issue number3
DOIs
StatePublished - Sep 2013
Externally publishedYes

Keywords

  • Abiraterone
  • Cabozanitinb
  • Docetaxel
  • Enzalutamide
  • Prostate cancer
  • Radium-223

Fingerprint

Dive into the research topics of 'The changing landscape in metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this